Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study - Concepedia

Concepedia

Publication | Open Access

Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study

DOI Full Paper Access

88

Citations

13

References

2015

Year

Ken Ohta, Masakazu Ichinose, Yuji Tohda, Michael E. Engel, Petra Moroni-Zentgraf, Satoko Kunimitsu, Wataru Sakamoto, Mitsuru Adachi

Abstract

ClinicalTrials.gov NCT01340209.

References

	Year	Citations

Page 1